Duchenne Community Punched Again: Akashi Suspends Trial
This article was originally published in Scrip
Executive Summary
The Duchenne muscular dystrophy (DMD) community was hit in the gut for the third time in the past few weeks with another setback in the development of a drug to treat the rare severely debilitating and fatal neuromuscular disease when Akashi Therapeutics Inc. disclosed it had suspended its HALO trial of its experimental therapy HT-100 after one patient receiving the highest dose experienced serious, life-threatening health issues.